| 摘要 |
<p>Patients suffering from a solid tumor disease selected from carcinoma of the bladder, renal carcinoma, squamous cell carcinoma of the skin, head and neck cancer, especially squamous cell head and neck cancer, lung cancer, especially non small cell lung cancer (NSCLC), tumors of the gastrointestinal tract, glioma and mesothelioma or metastases of such solid tumor diseases are treated with a 7H-pyrrolo[2,3-d]pyrimidine derivative.</p> |
